
|Articles|February 1, 2003
Established Paradigm
Paris - Combination immunotherapy for psoriasis is coming into the clinic. Experience is showing it can be a valuable strategy for increasing efficacy while minimizing toxicity, both acutely and potentially over the longer term, Christopher E.M. Griffiths, M.D., said at the World Congress of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














